News Category
A new expert consensus published in the World Journal of Pediatric Surgery provides 34 recommendations to standardize surgical management of unilatera...
VERAXA Biotech AG is advancing a diversified oncology pipeline with innovative antibody-based therapeutics, positioning itself in the fast-growing glo...
VERAXA Biotech started trading on the Nasdaq Capital Market under ticker VRXA, advancing a diversified oncology pipeline with its proprietary BiTAC pl...
Helix BioPharma Corp. reported a reduced net loss for the nine months ended April 30, 2026, and increased cash to $2.8 million, primarily from a priva...
Researchers at Florida International University have found a new way to boost the lifespan and effectiveness of CAR-T immune cells, potentially overco...
VERAXA Biotech, now trading on Nasdaq under VRXA, leverages its proprietary BiTAC platform to develop targeted antibody-based therapies for solid tumo...
Onco-Innovations Ltd. is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways, supported by five patents and...
Aptevo Therapeutics and Niowave have formed a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's tum...
A clinical trial called ROADS, presented at the 2026 ASCO meeting by MD Anderson Cancer Center, showed that placing radioactive collagen tiles in the ...
TransCode Therapeutics will host its first R&D webcast on June 18, 2026, to discuss its Phase 2a trial of TTX-MC138 in colorectal cancer and broader p...
Onco-Innovations Limited has signed a non-binding letter of intent with Nanosoft Polymers to support development of its oncology candidate ONC010 and ...
Oncotelic Therapeutics is combining its Deciparticle nanomedicine platform, PDAOAI artificial intelligence ecosystem, and robotics initiatives to impr...
Kairos Pharma announces plans to acquire CL-741, a Phase 1-ready oral c-MET kinase inhibitor, to expand its oncology pipeline, while advancing clinica...
TransCode Therapeutics announced positive Phase 1a trial results for its microRNA-10b inhibitor TTX-MC138, showing safety and durable disease stabiliz...
Revolution Medicines' new pill daraxonrasib targets KRAS mutations and has reportedly doubled survival in early trials, offering hope against a notori...
Lantern Pharma's LP-300 combination therapy shows improved progression-free survival in L858R-mutant non-small cell lung cancer patients, with FDA-cle...
A new inhalable viral-based vector could enhance the body's anti-cancer response and restore sensitivity to immune checkpoint inhibitors in advanced l...
Oncotelic Therapeutics is leveraging its Sapu003 program and Deciparticle platform to improve oncology drug delivery, aligning with a broader industry...
TransCode Therapeutics has launched a Phase 2a clinical trial of its lead candidate TTX-MC138 in colorectal cancer patients with minimal residual dise...
Onco-Innovations Limited reports progress in intermediate-scale manufacturing for its nanoparticle-formulated oncology candidate ONC010, moving toward...
A new doctoral study from Karolinska Institutet finds that young adults often suffer sexual problems after cancer treatment, with severity varying by ...
Lantern Pharma announced FDA acceptance of protocol amendments for its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-sma...
Oncotelic Therapeutics announced first-quarter financial results and progress across its oncology, AI drug development, and CNS delivery initiatives, ...
LIXTE Biotechnology announced first-quarter 2026 results showing advancement of its PP2A inhibitor LB-100 in ovarian cancer trials and growth at its L...
Lantern Pharma closed a $4.4 million registered direct offering, with potential additional proceeds from warrants, to advance its AI-driven oncology p...
A new preclinical study suggests that men with low testosterone levels have shorter survival times when diagnosed with glioblastoma, opening potential...
Kairos Pharma receives the 2026 GHP Magazine Healthcare & Pharmaceutical Award for its innovative work in developing cancer therapeutics that target d...
Oncotelic Therapeutics and Sapu Nano have dosed the first patient in a Phase 1b trial of Sapu003, a novel IV formulation of everolimus, aiming to impr...
Kairos Pharma's CEO will present on its clinical programs and partnering activities at the LD Micro Invitational, highlighting progress in cancer ther...
GeoVax Labs emphasizes the strategic role of its Gedeptin platform in enhancing checkpoint inhibitor efficacy against immunologically cold tumors by r...
OS Therapies Inc. has secured critical regulatory clarity from EMA and TGA for its OST-HER2 therapy, moving from Phase 2b toward a global approval pat...
A systematic review in JAMA Network Open suggests that earlier administration of immune checkpoint inhibitors could improve survival in patients with ...
Lantern Pharma announced expansion plans for its withZeta.ai platform, including ZetaSwarm and ZetaOmics, to enhance AI-driven oncology research and d...
Immunologists have discovered how cancer cells reprogram immune cells to support cancer growth, a finding that could help improve immunotherapy respon...
A clinical trial in Brazil reveals that daily vitamin D supplements improve chemotherapy outcomes for breast cancer patients, highlighting a low-cost,...
New research explains how age-related changes in breast tissue increase cancer risk, with implications for companies like Calidi Biotherapeutics.
Telomir Pharmaceuticals received FDA IND clearance to initiate a Phase 1/2 clinical trial for Telomir-Zn in advanced or metastatic triple-negative bre...
GeoVax Labs outlines near-term milestones for its oncology drug Gedeptin, including a planned Phase 2 trial in head and neck cancer and pursuit of par...
LIXTE Biotechnology is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and radiation efficacy while reducing side effect...
Scientists at Brown University Health have discovered a molecule with a dual mechanism that may improve outcomes for glioblastoma patients, with a cli...
LIXTE Biotechnology is developing LB-100, a small-molecule PP2A inhibitor that enhances chemotherapy and radiation efficacy while reducing side effect...
Lantern Pharma (NASDAQ: LTRN) will showcase its multi-agentic AI platform withZeta.ai in a live public demonstration on April 30, 2026, highlighting i...
Oncotelic Therapeutics is featured in a NetworkNewsAudio editorial discussing how late-stage drug pipelines drive biotech valuation, highlighting its ...
Oncotelic Therapeutics provided a corporate update emphasizing its partnership-driven approach to advance its oncology and rare disease pipeline, citi...
Oncotelic Therapeutics is highlighted in a BioMedWire editorial discussing how advancing drug pipelines are reshaping biotech valuations, with its AI-...
